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Photoreceptor Proliferation and Dysregulation of Cell Cycle Genes in Early Onset
Inherited Retinal Degenerations
Abstract

Background
Mitotic terminally differentiated photoreceptors (PRs) are observed in early retinal degeneration (erd), an
inherited canine retinal disease driven by mutations in the NDR kinase STK38L (NDR2).

Results
We demonstrate that a similar proliferative response, but of lower magnitude, occurs in two other early
onset disease models, X-linked progressive retinal atrophy 2 (xlpra2) and rod cone dysplasia 1 (rcd1).
Proliferating cells are rod PRs, and not microglia or Müller cells. Expression of the cell cycle related genes
RB1 and E2F1 as well as CDK2,4,6 was up-regulated, but changes were mutation-specific. Changes in
cyclin expression differed across all genes, diseases and time points analyzed, although CCNA1 and
CCNE1 expression increased with age in the three models suggesting that there is a dysregulation of cell
cycle gene expression in all three diseases. Unique to erd, however, are mutation-specific changes in the
expression of NDR kinases and Hippo signaling members with increased expression of MOB1and LATS1
in the newly generated hybrid rod/S-cones.

Conclusions
Our data raise the intriguing possibility that terminally differentiated normal PRs are kept from dividing by
NDR2-MOB1 interaction. Furthermore, they provide the framework for the selection of candidate genes for
further investigation as potential targets of therapy.
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Photoreceptor proliferation and
dysregulation of cell cycle genes in early
onset inherited retinal degenerations
Kristin L. Gardiner1, Louise Downs1, Agnes I. Berta-Antalics1,2, Evelyn Santana1, Gustavo D. Aguirre1*
and Sem Genini1*

Abstract
Background: Mitotic terminally differentiated photoreceptors (PRs) are observed in early retinal degeneration (erd),
an inherited canine retinal disease driven by mutations in the NDR kinase STK38L (NDR2).
Results: We demonstrate that a similar proliferative response, but of lower magnitude, occurs in two other early
onset disease models, X-linked progressive retinal atrophy 2 (xlpra2) and rod cone dysplasia 1 (rcd1). Proliferating
cells are rod PRs, and not microglia or Müller cells. Expression of the cell cycle related genes RB1 and E2F1 as well
as CDK2,4,6 was up-regulated, but changes were mutation-specific. Changes in cyclin expression differed across all
genes, diseases and time points analyzed, although CCNA1 and CCNE1 expression increased with age in the three
models suggesting that there is a dysregulation of cell cycle gene expression in all three diseases. Unique to erd,
however, are mutation-specific changes in the expression of NDR kinases and Hippo signaling members with
increased expression of MOB1 and LATS1 in the newly generated hybrid rod/S-cones.
Conclusions: Our data raise the intriguing possibility that terminally differentiated normal PRs are kept from
dividing by NDR2-MOB1 interaction. Furthermore, they provide the framework for the selection of candidate genes
for further investigation as potential targets of therapy.
Keywords: Canine models, Cell cycle, erd, Hippo pathway, Photoreceptor degeneration, Photoreceptor mitosis,
rcd1, xlpra2

Background
Photoreceptor (PR) cells are specialized retinal neurons that
efficiently capture light and transduce it into a neural signal.
Their intricate and highly specific structure is dependent
on the expression of multiple genes, including those
involved in PR specification, differentiation and maintenance [1]. Indeed, ~300 genes and loci are involved in retinal
degeneration in man (RetNet: http://www.sph.uth.tmc.edu/
RetNet/; October 2015), and a lower but still substantial
number of genes in animals [2, 3]. While mutations in PRspecific or enriched genes are common, and cause a broad
spectrum of inherited retinal diseases (reviewed by [4–6]),
an understanding of the mechanistic links between
* Correspondence: gda@vet.upenn.edu; geninis@vet.upenn.edu
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mutation and disease is limited. Moreover, while apoptotic
cell death is the final common pathway in most retinal degenerative diseases [7], the rate of degeneration and cell
death pathway utilized varies in a disease, mutation and
species-specific manner, demonstrating a high level of complexity [8–13]. Identifying the principal molecular players
and providing an in-depth knowledge of the mechanisms
that induce and regulate the underlying PR cell death will
provide essential insight into disease progression. This will
help to develop pharmacological agents and specific therapies that provide PR protection in the hopes of treating
inherited retinopathies.
While stimulating the proliferation of diseased yet
functional PRs to maintain the PR layer would likely be
therapeutically beneficial in some retinal degenerative
diseases, the proliferative potential of PR cells is controversial, and not well understood. PRs are terminally
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differentiated, and undergo their final cell division just
prior to cell fate specification; compensatory neurogenesis mechanisms do not exist to replace all dying cells in
the normal retina [1]. Indeed, it was originally postulated
that new PRs are generated in naturally occurring retinal
diseases, however this hypothesis has been disproved [14].
Furthermore, a recent comprehensive analysis of different
rodent retinal mutants, along with a light-induced retinal
degeneration model, clearly demonstrated that reactivation of the expression of cell cycle genes did not correlate
with PR cell division as determined by ethynyl deoxyuridine incorporation and phospho histone H3 (PHH3) labeling. Instead, this process was essential to promote the cell
death pathways [15]. In contrast, under some specific
circumstances [16], a limited number of PRs and other
neurons can be generated from presumably terminally
differentiated Müller cells that dedifferentiate, proliferate
and express neuronal progenitor markers in the adult rat,
mouse as well as chicken and fish (see for review [17]).
In contrast to normal PRs and other disease models,
we recently reported that a mutation in the NDR family
kinase STK38L (NDR2) found in the erd canine model
results in a period of sustained PR proliferation, and that
newly generated cells are unique hybrid rod/S-cones
[18], and did not originate from resident retinal stem
cells. The STK38L mutation eliminates the binding sites
for regulatory proteins S100B and MOB, and part of the
N-terminal regulatory region that is highly conserved in
all NDR subclass of AGC protein kinases [19]. NDR
kinases, including LATS1, interact with the Hippo pathway through MOB1 binding to regulate aspects of cell
growth, metabolism, proliferation and survival [20, 21].
Thus, we hypothesize that terminally differentiated
normal PRs are kept from dividing by NDR2-MOB1
interaction, and removing this control in mutants allows
the cell to re-enter the cell cycle and divide [18].
In the present study, we examined whether PR proliferation may also occur in other early-onset inherited retinal
diseases to determine if common molecular pathways
were involved. In addition to erd, where no equivalent disease has been reported in man [22], two other early onset
canine diseases with comparable cell death kinetics and
histopathology were examined: X-linked progressive
retinal atrophy 2 (xlpra2) and rod cone dysplasia 1 (rcd1),
which are caused, respectively, by mutations in
RPGRORF15 [23] and PDE6B [24]. Both diseases bear
mutations in genes that cause human inherited blindness, and the disease phenotypes are similar and comparable. In all three diseases, the early and rapid
degeneration of the PRs makes the disease course predictable and highly suitable for comparative studies of
the involved events. However, the exact mechanisms by
which mutations in these genes drive the degeneration
events are currently unknown.
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To this end, we examined the retinal and retinal pigment epithelium (RPE) expression of selected genes and
proteins that are involved in cell cycle regulation, or belong to the NDR protein-kinase family and the Hippo
pathway [15, 21]. Notably, our results indicate that PR
proliferation also occurred in xlpra2 and rcd1, but that
formation of hybrid rod/S-cones is unique to erd. Furthermore, we demonstrate a concurrent dysregulation of
critical cell cycle genes that were differentially expressed
(DE) in all three diseases, while Hippo pathway genes
were more specifically altered in erd.

Results
Morphology of early-onset canine retinal degeneration
models

We initially characterized the retinal morphology of the
3 early-onset disease models that generally have a similar
pattern of PR development and degeneration (Fig. 1).
Although overall retinal development is initially normal
(2 wks, data not shown), there were differences in the
subsequent rates and kinetics of PR degeneration; retinal
degeneration started at different ages and occurred more
rapidly in rcd1, where rod PR development was abnormal, and outer segments were sparse, failed to elongate,
and inner segments were short already at 4 wks. The
disease is slightly more delayed in xlpra2, while erd
showed preservation of the ONL thickness until at least
14.1 wks.
Photoreceptor cell proliferation in mutant retinas

To determine if PR proliferation was exclusive to erdmutants, we used PHH3 and PCNA labeling to examine
PR mitosis in the ONL of additional early-onset disease
models. PHH3 is a specific marker for mitotic cells in
the late G2 and M-phases [25], while PCNA labels both
cells undergoing proliferation and DNA repair [26]. The
number of labeled cells/1 million μm2 of ONL was analyzed at different time points between 2 and 20 wks. The
results showed similar trends for both PHH3 and PCNA
labeling in the different models and in normals (Fig. 2a
and b, respectively), although the number of PCNApositive cells was lower than the number of PHH3positive cells at every time point examined. In addition
to labeling different phases of the cell cycle, the lower
PCNA results suggest that there is limited ongoing DNA
damage and repair. Minimal numbers of PHH3-positive
cells were found in normal retinas after 2 wks of age;
these were located adjacent to the external limiting
membrane and limited to the retinal periphery.
As previously shown with PCNA labeling (Fig. 2b; [18]),
PHH3-labeled mitotic PRs were found at ≥7.7 wks in erd,
and these levels were sustained, ranging from >50–250
cells/1 million μm2 of ONL. In contrast, PR proliferation
peaked at 2 wks of age in rcd1 and at 8 wks in xlpra2.
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Fig. 1 Age-dependent structural changes in normal and mutant retinas. Disease occurs earlier and progresses more rapidly in rcd1, while it is
slightly delayed in xlpra2. The outer nuclear layer (ONL) in erd is preserved during the time course of the study. Scale bar: 20 μm; RPE = retinal
pigment epithelium, PR = photoreceptors, ONL = outer nuclear layer, OPL = outer plexiform layer, INL = inner nuclear layer, IPL = inner plexiform
layer, GCL = ganglion cell layer

These time points precede (5 wks in rcd1 and 11–12 wks
in erd) or approximately coincide (7 wks in xlpra2) the
peaks of cell death for each disease (reviewed in [13]).
However, regardless of the disease, the number of PHH3labeled cells in mutants far exceeded the numbers in
normals, and was sustained for the time period analyzed.
For example, at ~6 wks of age the mutants had 7–12 times
the number of dividing cells than controls, and these
increased to 12–42 times at ~8 wks.
We examined the association between cells undergoing mitosis (PHH3+), and those in mitotic checkpoint
arrest (MAD2+) to exclude the possibility that entry into
the late G2-M phase of the cell cycle preceded apoptosis.
To this end, we compared control (6 wks) and mutant
retinas at time points with high rates of PR mitosis in
mutants: xlpra2 = 8 wks, rcd1 = 6 wks, erd = 8.3 wks. In
the control, the PHH3 labeled ONL nuclei also labeled
with MAD2; overall, the number of labeled cells with
each antibody was low, and the PHH3/MAD2 ratio per
1 million μm2 of ONL was 1. In contrast, the PHH3/
MAD2 ratio in the mutants was much higher (xlpra2 =
2.5, rcd1 = 4.2, erd = 5.9), and smaller number of nuclei/

1 million μm2 of ONL co-expressed both proteins
(xlpra2 = 9, rcd1 = 25, erd = 16). This indicates that PR
mitosis is occurring in ONL, and the dividing cells contribute to maintenance of the ONL.
To control for the possibility that the same PR cells
were not undergoing concurrent apoptosis and mitotic
division, we performed dual-labeling with TUNEL and
PHH3 at the ages that correspond to the peaks of cell
death for each disease [13]. The results indicate that
with few exceptions the majority of cells were positive
for either TUNEL or PHH3, but not for both, an indication that different cell populations in the ONL were
undergoing either apoptosis or mitosis (Fig. 3A1–4). Colocalization of TUNEL and PHH3 labeling was rare and
limited to few cells (1–2 per sections that extend from
the optic nerve to the ora serrata) in the erd model.
These results establish that proliferating and degenerating cells in the ONL are different.
Mitotic cells in the ONL are rods

We used confocal microscopy in sections double-labeled
with PHH3 and rod opsin to determine if the proliferating
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Fig. 2 Photoreceptor cell proliferation in the outer nuclear layer of normal and mutant retinas. a PHH3-labeling was used to identify mitotic cells, and
b PCNA-labeling to identify cells undergoing proliferation and DNA repair. Normal retinas exhibited essentially no mitotic cells after 2 wks of age, while
they were present in the ONL of the 3 diseased retinas. Mitotic cells were continually present throughout the first 14–20 wks of life in all 3 diseases,
with the highest numbers observed in erd-mutants. The PCNA data for erd has been published previously (Fig. 3c in [18]). Data points are expressed as
mean of triplicates ± SD. Note the difference in the scale of the y-axes between erd (on right) and normal, xlpra2 and rcd1 (left)

cells in the ONL were rods. As rod opsin delocalizes to
the ONL in the early stages of disease [13], it serves as a
specific marker for rods. Confocal microscopy imaging
clearly demonstrated co-localization between PHH3 and
rod opsin, and revealed an opsin-positive cytoplasmic halo
surrounding the PHH3-positive cells in the ONL
(Fig. 3D1–3). These results indicate that in the three
diseases the proliferating cells in the ONL are rods. In
contrast, PHH3 labeling of putative cones, i.e. the larger
nuclei located immediately vitreal to the external limiting
membrane, was not detected.
Mitotic cells in the ONL are neither microglia nor
Müller cells

To determine if microglia or Müller cells contributed to
the pool of proliferating ONL cells observed with IHC,
we undertook dual-labeling with PHH3 and markers
specific for microglia (CD18; [27]) and Müller cells (glutamine synthetase (GS); [28]). CD18-labeled microglia
normally reside in the inner and outer plexiform layers
(IPL and OPL, respectively), and retinal diseases, in general, can result in microglial activation. However, neither
microglia (Fig. 3B1–4) nor Müller cells (Fig. 3C1–4) appeared to contribute to the PHH3 positive ONL cell
pool. It is important to note, however, that robust PHH3

labeling of GS positive Müller cells in the vitreal border
of the inner nuclear layer (INL) was present in some
areas of the rcd1 retina, and, to a lesser extent in xlpra2
(Fig. 3C2, 3); however there was no indication that these
dividing Müller cells migrated to the ONL.
Retinal gene expression
Age-dependent changes in normal and mutant
retinas – intra-group comparisons

To properly interpret gene expression changes that
occur with aging in both normals and mutants, we first
performed an intra-group comparison that examined expression at time points when PR and retinal development is occurring (3 wks), when they have just reached
structural maturation (5 and 7 wks) and when the retina
is fully mature (16 wks) [29] (Additional file 1). Overall,
the major changes in gene expression occurred between
7 vs. 3, and 16 vs. 3 wks, where many genes showed significant down-regulation compared to the previous time
point within each group, suggesting that the majority of
molecular events and changes take place when retinal
development is still ongoing before reaching maturation
(Additional file 1). With the exception of NR2E3, RB1,
E2F1, and CDK1, the expression profiles were not shared
between normal and mutant retinas. In the case of
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Fig. 3 PHH3 labeling identifies mitotic cells in the outer nuclear layer. a Combined PHH3 (red) and TUNEL (green) labeling in normal (A1, 6 wks),
xlpra2 (A2, 8 wks), rcd1 (A3, 6 wks) and erd (A4, 11.6 wks) retinas at the peak of cell death for each disease [13]. There are no TUNEL or PHH3
labeled cells in the normal retina. In the mutants, some of the red (PHH3) and green (TUNEL) labeled nuclei in ONL are identified. Note that in
erd (A4), two cells are undergoing combined proliferation and apoptosis (yellow arrows). b CD18 labeling (green) shows microglial cells and
processes distributed primarily in the OPL and IPL, with increased expression in xlpra2 (B2), rcd1 (B3) and erd (B4) compared to normal (B1).
PHH3 labeling in the mutants shows mitotic cells in ONL (red arrows). The two dividing cells in the OPL (B4, white arrows) are of unknown origin
and are not counted in the analysis. c Glutamine synthetase (GS) labeling in normal (C1), and dual PHH3 and GS labeling in xlpra2 (C2), rcd1 (C3)
and erd (C4). Dividing cells in ONL (red arrows) are not labeled with GS. Note that in xlpra2 and rcd1 there are PHH3-positive nuclei in the inner
border of the INL (white arrowheads). d Confocal microscopy image of dual-immunolabeling of retinal sections with PHH3 (red) and rod opsin
(green) in the ONL of xlpra2 (D1), rcd1 (D2), and erd (D3). The delocalized rod opsin associated with the cell membrane forms a green halo
around the labeled nuclei. RPE = retinal pigment epithelium, ONL = outer nuclear layer, INL = inner nuclear layer, IPL = inner plexiform layer,
NFL = nerve fiber layer. Scale bar: A-C = 40 μm; D = 5 μm

CDK1, expression was markedly up-regulated at 7 and
16 wks in normal, in rcd1 at 16 wks, and xlpra2 at 16 vs.
3 wks.
The expression of some cyclins decreased in normal
retinas over time, as expected by the lack of cell division
after two wks of age. However, this decrease was not accompanied by decreases in cyclin-dependent kinases, cell
cycle phosphatases, or cyclin-dependent kinase inhibitors. In contrast, cyclin-dependent kinases, CDK2, 4 and
6, decreased in expression in rcd1 at 7 compared to 3

wks; the former time point is characterized by a very
high rate of apoptotic PR cell death [13]. The expression
of the transcription regulators E2F1 and RB was lower at
all time points examined in xlpra2 in comparison to 3
wks of age. Two genes, CDK25B and CDKN1B were specifically up-regulated in erd at 8–10 and 11.9–14.1 wks
in comparison to 6.4 wks of age. Notably, there were no
changes in expression with age in members of the NDR
kinases or Hippo signaling pathway. Details of these results are presented in Additional file 1. All together,
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these results show that expression changes in the selected genes parallel the structural development of the
dog retina in normal and diseased retinas.
Disease associated changes in retinal gene expression

To determine the changes in expression as a result of
disease, we compared the mutant dogs to age-matched
normal controls at different ages. Concurrent with PR
cell degeneration, there is decreased expression of genes
associated with PR function and structure (Table 1).
GRK1 decreases first in rcd1 at 5 wks, and at 7 wks in
xlpra2. By 16 and 11.9–14.1 wks, RCVRN is decreased in
all 3 diseases. Consistent with incomplete outer segment
(OS) formation prior to early PR degeneration in rcd1
dogs, there is decreased expression of RDS at 5 wks and
subsequent time points. NRL and NR2E3, genes associated with PR development and cell fate specification [1],
are down-regulated in rcd1 at 5, 7 (NRL only), and 16
wks, and in xlpra2 also at 16 wks. NRL, the upstream
regulator of NR2E3, is down-regulated at all ages examined in erd, and may account for the formation of hybrid
rod/S-cones in the retina following PR cell proliferation
[18] (Fig. 4a, b).
Three cell cycle transcription regulators, BMI1, E2F1
and RB1, were included in the analysis. While BMI1
showed no changes associated with disease, both E2F1
and RB1 expression was up-regulated in xlpra2 and rcd1
at 3 wks, early in the degenerative process, and E2F1 at
the 16 wk time point. In contrast, there were marked
changes in expression of cyclin dependent kinases and
cyclins with disease (Table 1). CDK1 was down-regulated
in all diseases beginning at 5 wks in rcd1. CDKs 2,4,6 were
up-regulated at 3 and 16 wks in rcd1, and CDK6 at the
same time points in xlpra2. Up-regulation of CCNA2 and
CCNE1 occurred in the 3 mutants at 7 wks, and 16 wks
(CCNE1 only); similar up-regulation was found for
CCNA1 at 16 wks. Lastly, CCNB1, D1 and D3 were upregulated at 16 wks in rcd1, and CCNB1 and D1 in xlpra2
(Fig. 4c-e). These results indicate that changes in the
expression of some cyclin dependent kinases and cyclins
occur at specific disease stages, and, in some cases, the
expression patterns are shared among the 3 diseases.
Disease-associated changes in gene expression for
members of the NDR kinases and Hippo pathway were
only found in erd at the 11.9–14.1 wks time point. There
was up-regulation of LATS1, MOB1A and NDR1 (Fig. 4f ).
There were no expression differences in STK38L (NDR2),
the gene mutated in the disease when primers located 3′
to the deletion were used.
Disease-associated changes in RPE gene expression

Because of the close RPE-PR physical proximity, shared
functional interactions, and the RPE’s role in immune
modulation (reviewed by [30], we examined gene
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expression in the RPE to assess whether the observed retinal expression changes were specific, or also were present
in the RPE. To this end, a subset of the genes that were
DE in the retinal analyses were used to examine their expression in RPE/choroid samples in normal and mutant
retinas at different time points (Additional file 2). Even
though there was no evidence of RPE cell mitosis based
on PHH3 labeling, we did find that at 16 wks there was a
general up-regulation of CDK4, CCND1, and CCNE1 in
all three diseases. These expression commonalities suggest
that similar mechanisms related to the cell cycle pathway
might be activated and preserve the integrity in both mutant PRs and RPEs. As well, expression of the cell cycle
transcription regulator E2F1 was increased at 16 wks in
rcd1. In general, DE genes in retina and RPE samples were
not the same and the ages of dysregulation differed. In
contrast, as with the retinal analyses, expression changes
in NDR kinases and the Hippo signaling pathway were
only found in erd (Fig. 5a, b), although not at the same
ages and LATS2 was specifically DE only in RPE. These results indicate specific and likely independent differences
in the expression of cell cycle genes in the 2 different cell
types, and do not suggest a key role for RPE cells in retinal
degeneration.
Protein expression and disease
Western blot analyses

To complement the mRNA expression studies, we examined a selected number of proteins encoded by genes relevant to the cell cycle and PR cell fate specification, and
which were differentially expressed. In addition to NRL,
this included transcription regulators (pRB, E2F1), the
cyclin dependent kinase CDK4, cyclins (CCNA2, CCND1,
CCNE1), and the LATS1 and MOB1A members of the
NDR kinase/ Hippo signaling pathway (Fig. 6a, b). The
number of genes and time points tested was limited by
availability of samples, i.e. one sample/disease/time point,
and the lack of specificity to canine tissues for several of
the antibodies tested (see Additional file 3).
Relative to normal retina, NRL is down-regulated at 5
(data not shown), 7, and 16 wks in rcd1, and at 8.3 wks
in erd, which was the only time point examined by western blot analysis for the latter disease. This result is not
unexpected, as the transcription factor NRL is a critical
intrinsic regulator of PR development and function, and
regulates the expression of several rod-specific genes,
including RHO, that, particularly in rcd1, is also downregulated early in the disease process. The transcription
regulators pRB and E2F1 showed similar expression patterns with low levels in normal retinas, and higher levels
in the 3 disease models. CDK4 was lower in normals
and xlpra2 at 7 wks, while CCND1 and CCNE1 levels
were higher in all diseases. The levels of CCNA2 in the
7/8.3 wks diseased retinas were markedly higher. Lastly,

Gardiner et al. BMC Genomics (2016) 17:221

Page 7 of 18

Table 1 qRT-PCR retinal gene expression results in xlpra2, rcd1, and erd mutants compared to normal retinas
Ages
Gene

3 wks

5 wks

7 wks

n.s

n.s

n.s

16 wks

Cell cycle: cyclins
CCNA1

+4.4x in rcd1
+2.2x in xlpra2
+3.0x in erd (11.9–14.1 w)

CCNA2

n.s

n.s

+2.0x in rcd1

n.s

+2.2x in xlpra2
+2.2x in erd (6.4 w)
+3.2x in erd (8.3–9.9 w)
CCNB1

n.s

n.s

n.s

CCND1

n.s

n.s

n.s

CCND3

n.s

n.s

n.s

CCNE1

n.s

+2.4x in rcd1

+3.3x in rcd1
+2.8x in xlpra2
+2.4x in rcd1
+2.7x in xlpra2
+2.8x in rcd1

+2.7x in rcd1

+5.5x in rcd1

+4.1x in xlpra2

+5.1x in xlpra2

+2.8x in erd (6.4 w)

+10x in erd (11.9–14.1 w)

+5.7x in erd (8.3–9.9 w)
Cell cycle: cyclin-dependent kinases
CDK1

n.s

−2.1x in rcd1

−13.3x in rcd1

−2.2x in rcd1

−10.2x in xlpra2

−3.4x in xlpra2

−8.4x in erd (6.4 w)

−6.0x in erd (11.9–14.1 w)

−6.9x in erd (8.3–9.9 w)
CDK2

+2.7x in rcd1

n.s

n.s

+3.4x in rcd1

CDK4

+2.2x in rcd1

n.s

n.s

+2.4x in rcd1

CDK6

+3.6x in rcd1

n.s

n.s

+2.9x in rcd1

+2.5x in xlpra2

+2.1x in xlpra2

Cell division cycle phosphatases
CDC25A

n.s

n.s

n.s

n.s

CDC25B

n.s

n.s

n.s

n.s

CDC25C

n.s

n.s

n.s

+2.1x in rcd1
+2.7x in xlpra2

Cyclin-dependent kinase inhibitors
CDKN1A

n.s

n.s

n.s

n.s

CDKN1B

n.s

n.s

n.s

n.s

CDKN2A

−3.8x in rcd1

n.s

+3.0x in erd (8.3–9.9 w)

n.s

BMI1

n.s

n.s

n.s

n.s

E2F1

+2.0x in rcd1

n.s

n.s

+6.2x in rcd1

Cell cycle transcription regulators

+2.6x in xlpra2
RB1

+2.1x in rcd1
+5.5x in xlpra2

+3.7x in xlpra2
n.s

n.s

n.s
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Table 1 qRT-PCR retinal gene expression results in xlpra2, rcd1, and erd mutants compared to normal retinas (Continued)
Hippo signaling/NDR kinases
LATS1

n.s

n.s

n.s

+2.6x in erd (11.9–14.1 w)

LATS2

n.s

n.s

n.s

n.s

MOB1A

n.s

n.s

n.s

+2.5x in erd (11.9–14.1 w)

NDR1

n.s

n.s

n.s

+2.1x in erd (11.9–14.1 w)

STK38L (NDR2) (exons 4–5)

n.s

n.s

No expression in erd

No expression in erd

STK38L (NDR2) (exons 6–7)

n.s

n.s

n.s

n.s

Eye development regulation via proliferation/apoptosis
PAX6

n.s

n.s

−2.5x in erd (6.4 w)

+2.2x in rcd1

PCNA

n.s

n.s

n.s

n.s

n.s

−2.0x in rcd1

−3.9x in rcd1

−3.3x in rcd1

PR function
GRK1

−2.3x in xlpra2
RBP3

n.s

n.s

n.s

n.s

RCVRN

n.s

n.s

−2.6x in rcd1

−2.4x in rcd1
−2.2x in xlpra2
−2.0x in erd (11.9–14.1 w)

PR development/structure
CRB1

n.s

n.s

n.s

n.s

NRL

n.s

−2.3x in rcd1

−2.0x in rcd1

−3.0x in rcd1

−3.2x in erd (6.4 w)

−2.0x in xlpra2

−3.7x in erd (8.3-9.9 w)

−5.8x in erd (11.9–14.1 w)

NR2E3

n.s

−2.0x in rcd1

−2.8x in erd (6.4 w)

n.s

RDS

n.s

−2.5x in rcd1

−2.0x in rcd1

−3.0x in rcd1

Statistically significant (p < 0.05 and FC > +/−2) differences in retinal gene expression are reported in comparison to normals at different ages (rcd1 and xlpra2: 3,
5, 7, 16 wks; erd: 6.4, 8.3–9.9, 11.9–14.1 wks). The examined genes are reported in alphabetical order within functional groups. The complete list of genes tested is
available as Additional file 5. n.s = not statistically significant; + = up-regulated and - = down-regulated compared to normal

we found that expression of MOB1A was specifically
elevated in erd, but LATS1 was increased in rcd1 and
erd at ~7 wks. In general, there was good agreement
between the qRT-PCR and western analyses, which indicate a dysregulation of the expression of some cell cycle
proteins in the canine models studied.
Immunohistochemistry

We used IHC to localize the expression of selected proteins, and to qualitatively assess their expression levels.
While expression of CRX, a PR-specific transcription
factor that plays a role in the differentiation of PR cells,
was low in all samples, regardless of disease status, the
expression of NRL differed in normal and mutants. Normal retinas showed labeling in the cone outer segments
and basal row of ONL nuclei. Similar OS labeling was
found in xlpra2 and rcd1, but with a larger area of the
ONL occupied by labeled nuclei. In contrast, the erd retina, composed primarily of hybrid rod/S-cones, had a
paucity of NRL-labeled cone outer segments, further
underlying this particular feature of this disease model.

On the other hand, PAX6, a transcription factor present
in developing eyes, primarily labeled Müller cell nuclei
in normal and mutants, but not PRs (Fig. 7A-C).
Due to lack of specificity, we were unable to assess
immunolabeling with cell cycle specific antibodies against
pRB1, CDK1, CDK2, and CCNA2 (Additional file 3). Antibodies against E2F1 showed robust labeling localized to
the RPE, IPL and especially the OPL. Mutant retinas, particularly at younger ages, showed more intense RPE labeling (Fig. 8A). Of the 2 cyclins analyzed, CCND1 primarily
showed intense labeling over the RPE layer, and, with the
exception of erd, was more intense than in controls. In
most cases, the labeling was cytoplasmic as well as nuclear
(Fig. 8B). In contrast, CCNE1 labeled horizontal processes
in the OPL equally in normals and mutants (Fig. 8C).
Immunolocalization of MOB1A was comparable in
normal and mutants, and in xlpra2 and rcd1 for LATS1
(Fig. 9A, B). In erd, however, more diffuse labeling of the
PR layer was evident with LATS1. With OS-2, a monoclonal antibody that specifically labels S-cones [31], we
found labeling of a distinct population of S-cone in
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Fig. 4 Retinal mRNA expression changes in xlpra2, rcd1, and erd-mutants compared to normal between 3 and 16 wks of age. a Photoreceptor function;
b Photoreceptor development/structure; c Cell cycle transcription regulators; d Cyclin-dependent kinases; e Cyclins; f Hippo signaling/NDR kinases. An
asterisk indicates statistically significant differences (p < 0.05; fold change > +/−2) in expression. Data points are reported as mean +/− SD

normal, xlpra2 and rcd1 (Fig. 9C1–3). In erd, however,
the OS-2 antibody resulted in uniform labeling of the
entire PR layer (Fig. 9C5). The merged OS-2 and LATS1
images showed no co-localization in normal (Fig. 9C4),
but complete co-localization in the PR layer of erd
(Fig. 9C6). These results confirm a previous study which
described that newly generated PRs in erd are hybrid
rod/S-cones [18], and indicates that in erd the LATS1
protein is now expressed in these newly formed cells.

Discussion
Cell division in normal canine retina ends before 2 wks
of age, and PRs mature in the first 5–8 wks after birth
[29]. PR proliferation beyond 2 wks occurs infrequently,
sporadically, and only in the periphery, adjacent to the ora
serrata. In contrast, mitotic PRs are observed in one
inherited retinal disease, erd, in which concurrent
proliferation and apoptosis of different PR cell populations occurs, and is followed by formation of hybrid
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rod/S-cones. The cell proliferation and death kinetics
are balanced, albeit for a finite period, as the ONL
maintains normal thickness until 14 wks of age.
Thereafter, the balance tilts towards cell death and
the ONL progressively thins [18].
To determine if aberrant PR proliferation is exclusive
to erd, we assessed two other phenotypically comparable
diseases, xlpra2 and rcd1, and used erd as a mutant control. These diseases are caused by mutations in distinct
genes that impair the early phases of PR development,
and, generally, have similar structural features and disease time course with rcd1 being faster and more aggressive, followed by xlpra2 and erd [13]. Using PHH3
as a specific marker of the M-phase of the cell cycle, we
identified mitotic cells in the ONL in all three diseases,
with the greatest number observed in erd. PCNA labeling largely recapitulated trends in PHH3 labeling over
time, and the highest numbers of PCNA-positive cells
were identified in erd. Confocal microscopy demonstrated conclusively the co-localization of PHH3 with
the rod-specific protein RHO, and confirmed that cells
undergoing proliferation in all 3 diseases were rod PRs.
The higher overall numbers of PHH3-positive than
PCNA-positive cells suggests that the majority of proliferating cells in the ONL are in the M-phase of the cell

cycle for all 3 diseases. In xlpra2 and particularly in
rcd1, there is marked PR proliferation that is many times
higher than that found in normals. In both, proliferation
is sustained for the 20 wk period of observation. The
magnitude of PR proliferation in the two diseases parallels cell death kinetics based on TUNEL labeling, which
is greater in rcd1. Balance between cell proliferation and
death in these two diseases does not occur, and the ONL
progressively thins beginning at early time points [13].
The overall lack of co-localization of TUNEL- and
PHH3-labeled PR cells indicated that different cells
undergo proliferation and apoptosis, and that the two
events are not linked in a common pathway. Furthermore, the large differences between the number of cells
labeled with PHH3 and MAD2, and the smaller number
of cells that co-express both markers in the mutant retinas emphasizes that the cells entering the M-phase of
the cell cycle do not undergo mitotic checkpoint arrest,
but continue to divide, thus contributing new PR cells to
the ONL. In contrast, the control retina showed only a
very small number of PHH3 positive cells, and all of
these co-expressed MAD2.
In rd1 mice, proliferating cells in the ONL have been
reported to be microglia in origin, based on F4/80
immunostaining [14]. In contrast, although the mutant
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Fig. 6 Western blot analysis of normal, xlpra2, rcd1, and erd retinas.
a Blots exposed on autoradiograph films; b Li-COR immunoblotting
system. The band intensity normalized to the actin density of the
normal control (7 wks for ages 7 and 8.3 wks; 16 wks for 16 wk
mutant samples) was set to one, and fold changes were calculated
and shown below each of the blots

canine retinas showed an increased numbers of CD18positive microglial cells and processes, these did not colocalize with PHH3 labeling. In addition, GS-positive
Müller cell labeling did not co-localize with the dividing
PR cells. While the methods used cannot exclude completely a contribution by microglia and/or Müller cells
to the dividing cell population in the ONL, the results
indicate that such a contribution, if present, is minor. It
is possible that some of the PHH3-labeled Müller cells
in the vitreal border on the INL in xlpra2 and rcd1 (see
Fig. 3C2,3), proliferated and migrated into the ONL.
However, prior studies have shown that PAX6 positive
Müller glia can express cell cycle markers, but not proliferate [32]. All together, our results show that in the
ONL of the 3 canine diseases there are distinct subsets
of PR cells one that is dying, while the other is dividing.
A recent study showed that in several rodent models of
retinal degeneration there is a reactivation of cell cycle
genes before the onset of apoptosis [15]. These findings
were in accord with previous studies of neurodegenerative
diseases, e.g. Alzheimer disease, Parkinson’s disease and
others, where aberrant reentry of susceptible neuronal
populations into the cell cycle is associated with the death
of post-mitotic, terminally differentiated neurons [33–36].
In the retina of the rodent models, nuclear expression of
CDK4, CDK6, and CDK2, as well as phosphorylation of
Rb precede PR death. Furthermore, deleting E2F1 in the
rd1 model resulted in a transient neuroprotection,
whereas deletion of BMI1, the upstream activator of E2F1
and CDKs, resulted in a marked delay in PR loss. At least
in the rodent retinas, re-activation of these cell cycle proteins resulted in PR cell death, but not PR mitosis [15].
Unlike these rodent models, PR proliferation is readily
observed in 3 early-onset canine models of retinal degeneration (current study and [18]). To begin to assess
the mechanistic basis for PR proliferation, we first examined selected genes involved in different phases of the
cell cycle. We find that at 3 and 16 wks, the first and last
time points examined, mRNA expression of RB1 and
E2F1 are significantly up-regulated in xlpra2 and rcd1,
and protein levels of pRB1 and E2F1 were increased in
all 3 diseases. Expressions of CDK2,4,6 also are upregulated at the same time points, particularly in rcd1,
but CDK1 expression is down-regulated. Indeed, western
analysis of CDK4 showed increased expression at 7 wks
in mutants. Furthermore, mRNA expression changes in
cyclins were quite uniform across all diseases; CCNA2
and CCNE1 were up-regulated at 7 wks, while increased
expression of the other cyclins was found at the 16 wk
time point. These data were confirmed by western analysis, showing comparable results at the mRNA and protein levels. These results indicate that in the mutant
canine retinas there is a dysregulation of cell cycle gene
expression in comparison to the normal retina.

Gardiner et al. BMC Genomics (2016) 17:221

normal

Page 12 of 18

xlpra2

rcd1

erd

CRX

A1

A2

A3

A4

B2

B3

B4

C2

C3

C4

NRL
PR

B1
PAX6
ONL

INL
IPL

C1

NFL

Fig. 7 Immunolabeling in normal and mutant retinas for retinal transcription factors. A CRX; B NRL; C PAX6. Samples were from normal (7 wks),
xlpra2 (8 wks), rcd1 (7 wks) and erd (CRX-9.1 wks; NRL-7.7 wks; PAX6-14.1 wks). In normal, xlpra2 and rcd1, NRL is expressed in cone outer segments
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no rod outer segments remain so NRL distinctly labels the surviving cone outer segments. PR = photoreceptor, ONL = outer nuclear layer, INL = inner
nuclear layer, IPL = inner plexiform layer, NFL = nerve fiber layer. Scale bar = 40 μm

Even though the 3 diseases investigated are primary
PR degenerations, we also examined the RPE expression
changes of selected genes, to determine potential differences or commonalities. We find altered mRNA expression patterns in the RPE at time points when this cell
layer is not affected. At 16 wks of age, DE genes were
primarily up-regulated, and included CDK4, CCNA1,

normal
7 wks

and CCNE1, which showed increased expression levels
in the three diseases. At 7 weeks, on the other hand, statistically higher mRNA levels were observed mainly in
erd, and included NDR1 and LATS1, while, as expected,
STK38L expression of exon 4, deleted in the disease, was
absent. Other than CCNE1, there was poor correlation
between the retina and RPE mRNA expression findings
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Fig. 8 Immunolabeling in normal and mutant retinas for selected cell cycle proteins. Paired sections from normal, xlpra2, rcd1, erd retina taken at two
ages were labeled with antibodies against: A E2F1, B CCND1, C CCNE1. More intense labeling of the RPE layer is present in mutants compared with
normals with antibodies against E2F1 and CCND1. Note that in the 16 wk xlpra2 retina (B2), the RPE layer has separated from the section during
immunolabeling and is not included in the image. RPE = retinal pigment epithelium, ONL = outer nuclear layer, OPL = outer plexiform layer, INL = inner
nuclear layer, IPL = inner plexiform layer, NFL = nerve fiber layer. Scale bar = 40 μm
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at comparable ages. These results are not unexpected
given that the PRs are affected by the disease. Indeed,
changes in the RPE occur in response to PR degeneration or alternatively could be due to changes in
contaminating tissue, including choroid, microglia/macrophages and white blood cells trapped in the highly vascular choroid. However, in contrast to the retina, the
observed differences in RPE cell cycle gene expression in
the 3 diseases suggests an activation of pathways that
lead to the long-term survival. This hypothesis warrants
further studies that could also be performed on primary
RPE cell cultures.

While the mRNA and protein expression studies indicate activation of a subset of cell cycle genes in proliferating PR, some of the IHC results are more difficult to
reconcile with these findings given the apparent lack of
specificity of several of the antibodies. In tissue sections,
we could not assess expression of pRB1, CDK1, CDK4,
CCNA2, CCNB1, and CCND3. Moreover, in none of the
mutant tissues that showed PHH3-labeled proliferating
PRs did we find labeling with E2F1, CCND1 or CCNE1
in the ONL, the expected site of these cellular events.
Obviously, both qRT-PCR and western analyses include
the entire neuroretina, while proteins with IHC were
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more precisely localized to specific cellular layers, but
quantification of labeling intensity is qualitative. These
data suggest that the cells expressing different levels of
cell cycle-related transcripts may not be the ones that
are dividing, thus are not PRs. The specific analysis of
these questions will require single cell analysis of PR
populations. In contrast to the retina, IHC of the RPE
clearly showed expression of several of the cell cycle
gene products, e.g. E2F1 and CCND1. Labeling intensity
was greater in the mutants vs. controls, and there was a
general increase in label intensity in the older affected
animals of each genotype. This evidence appears to confirm an activation of specific cell cycle related pathways
in RPE that might promote survival of these cells.
Most notably, we find unique changes in the expression of NDR kinases and Hippo signaling genes in erdmutants, a disease caused by a mutation in the NDR
kinase STK38L (NDR2). We found an up-regulation of
the NDR kinases and Hippo signaling pathway members
MOB1A, LATS1, and NDR1. LATS1 is a tumor suppressor gene expressed in vertebrate retina [37] and stimulates the kinase activity of STK38L upon MOB1A
binding and subsequent activation after association with
S100B [38, 39]. The increased expression of LATS1 in
erd may be an attempt to suppress the aberrant PR proliferation or to induce apoptosis, as several studies have
reported this particular feature of this gene [40–42].
LATS1 and OS-2 co-localization in the PR inner and
outer segments was observed with IHC exclusively in erd,
and confirms the previous finding that aberrant rod/Scone hybrids are generated following PR proliferation in
erd-mutants [18]. Finding marked down-regulation of expression of NRL in erd is also consonant with its known
function in PR cell fate specification [1]. NRL knockout
mouse retinas are almost entirely composed of S-cone
PRs. Given that the proliferating population of PRs in the
erd retina resulted in L/M-cone and hybrid rod/S-cones,
the decreased expression of NRL is not surprising.
The Hippo pathway controls organ size via the regulation
of apoptosis and proliferation. It interacts in cell cycle control by CDK1 phosphorylation of YAP, a downstream
Hippo pathway effector [43], and cyclin E is a known Hippo
pathway target gene [44]. Indeed, the Hippo pathway, via
MOB1A activation of LATS1 tumor suppressor can negatively regulate cell proliferation by modulating cyclin A activity [40]. However, as we found that expression changes
in CDK1, CCNE1, CCNA1, and CCNA2 were not specific
to erd, but were comparable also in xlpra2 and rcd1, we expect that the observed retinal changes in these genes did
not result from the altered Hippo signaling pathway.

Conclusions
In summary, our results show that in early phases of
three retinal degenerative diseases in dogs, PHH3
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labeling is present in the outer nuclear layer, an indication that a subset of PR cells have entered the M-phase
of the cell cycle. These cells are of rod origin, and there
is no evidence that the proliferating cells are microglia
or Müller cells. In erd, the proliferating cells transiently
maintain the integrity of the ONL in spite of high rates
of concurrent apoptotic cell death in cells that are not
proliferating (present study; [18]). Similar but lower
levels of PR proliferation occur in xlpra2 and rcd1, but
the high rate of apoptotic cell death in comparison to
PR proliferation result in a more rapid loss of ONL in
the early stages of disease. Associated with these events
is a dysregulation of cell cycle genes that appears to
occur in a different subset of retinal cells, that might
play a primary or bystander role in the degenerative
process.

Methods
Ethics statement

The research was conducted in full compliance with the
University of Pennsylvania Institutional Animal Care
and Use Committee (IACUC) approval, adhered to the
Association for Research in Vision and Ophthalmology
(ARVO) Resolution for the Use of Animals in Ophthalmic
and Vision Research, and followed the recommendations
in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. All efforts were made
to minimize suffering in the study animals.
Samples

Retinal and RPE/choroid samples from dogs with a common genetic background, but which segregated with
either normal, xlpra2, rcd1, or erd alleles were used. The
majority of samples for immunohistochemistry (IHC)
and quantitative Real Time-PCR (qRT-PCR) represented
archival tissues previously collected for recently published studies [13, 18, 45]; additional samples were
collected to complete additional time points. Details
of the samples and ages studied are summarized in
Additional file 4.
The studied diseases were: 1) X-linked progressive
retinal atrophy 2 (xlpra2), an early-onset progressive rod
and cone disease with a 2-bp micro-deletion in retinitis
pigmentosa GTPase regulator (RPGR) exon ORF15 that
causes a frameshift and premature stop codon in the
translated protein [46]; 2) Rod cone dysplasia 1 (rcd1),
an early-onset autosomal recessive rod disease caused by
a nonsense mutation in the rod cyclic GMPphosphodiesterase beta-subunit (PDE6B), which results
in a stop codon and truncation of the terminal 49 amino
acids [24, 47]; and 3) early retinal degeneration (erd), an
autosomal recessive disorder of rods and cones caused
by an insertion in exon 4 of the serine/threonine kinase
38-like protein (STK38L/NDR2) [22, 29]. For the present

Gardiner et al. BMC Genomics (2016) 17:221

studies, we focused on the most relevant disease-related
phases of PR cell death: before cell death peak (induction: 3 wks), at cell death peak (execution: 5–10 wks),
and during sustained but reduced cell death rate (chronic
cell death: ≥ 14 wks) [13].
Gene expression quantification

qRT-PCR was performed with strict adherence to the
guidelines for minimum information for publication of
quantitative real-time PCR experiments (MIQE) [48].
Method details have been published previously [13, 45].
Canine-specific gene amplification was done using either
Taqman assays (Applied Biosystems) or primers designed
with Primer Express Software v3.0 (Applied Biosystems)
using SYBR green (Additional file 5). CT values of each
gene were normalized to those of GAPDH, the most stable
housekeeping gene [13], and comparisons between groups
were performed with the ΔΔCT method [49]. Statistical
significance of differentially expressed genes (p < 0.05; fold
change FC > +/−2) was assessed with an unpaired t-test.
Additional file 4 details the samples (n = 3) for each time
point and disease.
Selection of the examined genes

Selection of genes examined in this study (Additional
file 5) was mainly based on prior characterization of
erd-mutants [18]. As PR proliferation was observed in
erd [18], and reactivation of cell cycle proteins accompanies retinal degeneration in rodents [15], we examined retinal expression of a selected number of cell
cycle genes belonging to different categories, including
cyclins, cyclin-dependent kinases, cell division cycle
phosphatases, cyclin-dependent kinase inhibitors, transcription regulators, and selected members of the NDR
kinase and Hippo pathway. Genes involved in eye
development regulation via proliferation/apoptosis, PR
function and development were also evaluated. For the
RPE, a smaller subset of non-PR enriched genes was examined. Additional file 5 summarizes the examined genes
and their main function.
Western blot analysis

Equal amounts (60 μg) of total protein as determined by
BCA Protein Assay Kit (Thermo Fisher Scientific,
Rockford, IL) were separated by 10 % SDS-PAGE under
reducing conditions, immunoblotted, and probed with
antibodies as previously described [13]. Details on the
tested primary antibodies, including their concentrations,
are shown in Additional file 3. HRP-conjugated secondary
antibodies (Thermo Fisher Scientific) were used at concentrations of 1/10,000 with ACTB as a loading control,
and exposed on autoradiograph films (Eastman Kodak, XoMAT; Rochester, NY). A small subset of proteins was analyzed using the Li-COR Infrared Imaging immunblotting
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system (Li-COR Biosciences, Lincoln, NE). These were
then transferred to nitrocellulose membranes (Li-COR)
using the Wet/Tank Blotting System (BioRad) and blocked
with Odyssey Blocking Buffer (Li-COR) for 1 h at room
temperature. Membranes were then incubated overnight
at 4 °C with primary antibodies (Additional file 3) in
Odyssey Blocking Buffer containing 0.1 % Tween 20. After
primary antibody incubation, membranes were washed
with PBS containing 0.1 % Tween 20 (PBST), and incubated for 1 h at room temperature in goat anti rabbit
IRDye680RD- and goat anti mouse IRDye800CWconjugated IgG secondary antibodies (Li-COR) diluted
1/10,000 each in Odyssey Blocking Buffer containing
0.1 % Tween 20. Immunoblots were washed in PBST
three times, PBS once, and scanned on Li-COR Odyssey
Fc Dual-Mode Imaging System with 700- and 800-nm
channels and using the Image Studio Software. Normalization of samples against ACTB was done using
Li-COR software for all blots.
Immunohistochemistry (IHC)

Standard IHC labeling: retinal localization of selected
proteins (Additional file 3) was performed by IHC using
methods previously described [13, 18]. Slides were
incubated overnight with one (or two for dual-labeling)
primary antibodies, subsequently incubated with
fluorochrome-labeled secondary antibodies (Alexa Fluor
568 or 488, Invitrogen, Carlsbad, CA), and cell nuclei
stained with DAPI (49,69-diamino-2-phenylindole).
Low pH Antigen Retrieval (AgRet): with E2F1 and
MAD2, as well as other not specific or not working
antibodies, a low pH antigen retrieval (AgRet) step was
used prior to immunolabeling. Tissues were incubated
in TBST (1X TBS/0.1 % Tween 20/ 0.02 sodium azide)
for 5 min. Fifty milliliters 1x Antigen Unmasking
Solution, Low pH (Vector Laboratories Inc, California,
USA) was added to a coplin jar containing the tissue
slides and transferred to a decloaking chamber
(Biocare Medical, Concord, CA, USA) at 125 °C for
90 sec (pressure 25 lb) followed by 90 °C for 10 sec.
Tissues were next incubated with 1X TBST for 10 min
and washed with 1X PBS for 5 min each. Immunolabeling was then performed as noted above for standard
IHC labeling.
PHH3 and PCNA single and dual labeling: to identify
outer nuclear layer (ONL) cells that undergo mitosis, we
used the PHH3 antibody that distinguishes mitotic cells
from apoptotic cells and karyorrhectic debris [50]. The
proliferative cell nuclear antigen (PCNA) antibody was
used to identify cells that are proliferating and/or undergoing DNA repair [26], while the MAD2 antibody was
used to identify those cells in mitotic checkpoint arrest
[51]. Finally, to detect apoptotic ONL cells we used the
TUNEL (terminal deoxynucleotidyl transferase mediated
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biotinylated UTP nick end labeling) in situ cell death detection kit (Roche Applied Science, Indianapolis, IN).
To analyze PHH3 and PCNA single and dual labeling,
we used the standard IHC protocol [13, 18] with the following modifications. Prior to the initial treatment with
1x PBS/0.25 % triton X-100, single (PHH3, PCNA) or
dual-labeled (PHH3 with CD18, rod opsin, TUNEL, and
Glutamine Synthetase - GS) sections were boiled in
coplin jars containing high pH antigen unmasking solution (Vector Laboratories) in a 600 watt microwave at
30 % power for 10 min, cooled at room temperature for
30 min, and washed 2x with PBS. The samples were
then processed using standard IHC methods for dual
labeling.
TUNEL and PHH3 dual-labeled sections were
cooled for 45 min, blocked with 10 % goat serum,
incubated in 0.1 % Triton X-100/0.1 % Na citrate
permeabilization solution, and washed 2x in PBS. A
total of 50 μL TUNEL reaction mixture was added
for 1 h at 37 °C in the dark, while negative controls
only received 50 μL label solution. Slides were then
rinsed 3x with PBS and incubated with the PHH3
antibody as described above. For PHH3/MAD2 dual
labeling, the previously described low pH AgRet
method was used, with an additional dual labeling
step for MAD2.
Positive cells in the ONL were counted in triplicate
under fluorescent microscopy for the entirety of each
retina section. The number of positive cells was then
normalized to the calculated area of the ONL using a
conventional hematoxylin and eosin (H&E) stained
image from a serial section congruent with the fluorescently labeled slide. Details of the cell counting and analysis methods are shown in [13, 18].
IHC Imaging: The Gelvatol (pH = 8.5; Sigma-Aldrich)mounted slides were examined with an epifluorescence
microscope (Axioplan; Carl Zeiss Meditec, Thornwood,
NY). Epifluorescence or transmitted light images were
captured with a Spot 4.0 camera (Diagnostic Instruments Inc., Sterling Heights, MI) and displayed with
Photoshop and Illustrator (Adobe, San Jose, CA). In
addition, dual-labeled slides with PHH3 and rod opsin
antibodies were visualized with a Leica TCS SP5 II scanning laser confocal microscope (Leica Microsystems,
Wetzlar, Germany) with a resonant scanner for single
cell antibody co-localization analysis. For each antibody,
control and affected dogs were processed at the same
time with the same antibody concentration and lot
number; when capturing images for documentation,
the same magnification and camera settings were used
in all the samples. For those proteins involved in cell
cycle, tonsil and thymus tissues from an 11.7 wk old
normal dog were used to confirm specificity of
immunolabeling.
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Availability of supporting data

The datasets supporting the conclusions of this article
are included within the article and its additional files.

Additional files
Additional file 1: qRT-PCR retinal gene expression results during
development in normal, xlpra2, rcd1, and erd. Statistically significant
(p < 0.05 and FC > +/−2) gene expression differences are reported
between different developmental ages (within group comparison) in
each of the normal, rcd1, xlpra2, and erd groups. (DOCX 30 kb)
Additional file 2: qRT-PCR expression results in the RPE of xlpra2,
rcd1, and erd mutants compared to normal. Statistically significant
(p < 0.05 and FC > +/−2) gene expression differences are reported in each
of the rcd1, xlpra2, and erd groups compared with normals at different
ages (3, 7, and 16 wks). (DOCX 18 kb)
Additional file 3: List of antibodies used for immunohistochemistry
(IHC) and western blot (WB). Antibodies are reported with the symbol
of the corresponding protein, source (commercial company name and
catalogue number or the name of the person who provided it), description
of host and antibody type (polyclonal or monoclonal), concentrations used
for either IHC or WB and the expected size of the protein in kDa.
(DOCX 16 kb)
Additional file 4: Summary of diseases and ages tested in the
different study procedures. The table summarizes the number and
ages of the dogs tested for each tissue type in the different procedures
(i.e. qRT-PCR, western blot analysis, and IHC/morphology). (DOCX 16 kb)
Additional file 5: Genes tested by qRT-PCR in retina and RPE. The
complete list of all the genes examined by qRT-PCR is reported, with
gene symbols and alternative symbols, gene names, main functions, and
TaqMan assay numbers (ABI; http://www3.appliedbiosystems.com/
AB_Home/index.htm) or primer sequences. (DOCX 22 kb)

Abbreviations
The gene symbols and corresponding gene descriptions of all the genes
tested are shown in Additional file 5. ABI: Applied Biosystems; AgRet: antigen
retrieval; ARVO: association for research in vision and ophthalmology;
BH: Benjamini Hochberg; Da: Dalton; DAPI: 49,69-diamino-2-phenylindole;
DE: differentially expressed; erd: early retina degeneration; FC: fold change;
FFB: Foundation Fighting Blindness; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; GCL: ganglion cell layer; GS: Glutamine Synthetase;
H&E: hematoxylin and eosin; IACUC: Institutional Animal Care and Use Committee;
IHC: immunohistochemistry; INL: inner nuclear layer; IPL: inner plexiform layer;
IS: inner segment; MAD2: Mitotic Arrest Deficient-2; MIAME: minimum information
about a microarray experiment; MIQE: minimum information for publication of
quantitative real-time PCR experiments; n.s: not statistically significant; n.t: not
tested; NFL: nerve fiber layer; ONL: outer nuclear layer; OPL: outer plexiform layer;
OS: outer segment; PCNA: proliferative cell nuclear antigen; PDE6B: rod cyclic GMP
phosphodiesterase 6 ß subunit; PHH3: phospho histone H3; PR: photoreceptor;
qRT-PCR: quantitative real-time PCR; rcd1: rod cone dysplasia 1; RPE: retinal
pigment epithelium; RPGR: retinitis pigmentosa GTPase regulator; SD: standard
deviation; STK38L: serine/threonine kinase 38 like; TUNEL: terminal
deoxynucleotidyl transferase mediated biotinylated UTP nick end labeling;
WB: western blot; wks: weeks; xlpra2: X-linked progressive retinal atrophy 2;
XLRP: X-linked retinitis pigmentosa.
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